GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Olymvax Biopharmaceuticals Inc (SHSE:688319) » Definitions » 5-Year RORE %

Chengdu Olymvax Biopharmaceuticals (SHSE:688319) 5-Year RORE % : -9.58% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chengdu Olymvax Biopharmaceuticals 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % for the quarter that ended in Dec. 2024 was -9.58%.

The industry rank for Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % or its related term are showing as below:

SHSE:688319's 5-Year RORE % is ranked worse than
54.82% of 1140 companies
in the Biotechnology industry
Industry Median: -6.455 vs SHSE:688319: -9.58

Chengdu Olymvax Biopharmaceuticals 5-Year RORE % Historical Data

The historical data trend for Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Olymvax Biopharmaceuticals 5-Year RORE % Chart

Chengdu Olymvax Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 38.54 -9.58

Chengdu Olymvax Biopharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.54 -2.81 -37.91 -21.48 -9.58

Competitive Comparison of Chengdu Olymvax Biopharmaceuticals's 5-Year RORE %

For the Biotechnology subindustry, Chengdu Olymvax Biopharmaceuticals's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % falls into.


;
;

Chengdu Olymvax Biopharmaceuticals 5-Year RORE % Calculation

Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 0.051-0.099 )/( 0.539-0.038 )
=-0.048/0.501
=-9.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 5-year before.


Chengdu Olymvax Biopharmaceuticals  (SHSE:688319) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Chengdu Olymvax Biopharmaceuticals 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Chengdu Olymvax Biopharmaceuticals's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Olymvax Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
Executives
Chen Dao Yuan Core technical personnel
Li Hong Guang Core technical personnel
Fan Shao Wen Directors, senior managers
Ma Heng Jun senior management
Wu Wei senior management
Fan Fan Director
Chen Ai Min Director
Tan Yong senior management
Lu Lu Director
Yu Yun Hui Director
Zhang Li Ying Core technical personnel
Chen Ke Ping Core technical personnel
Wu Qiang Core technical personnel
Yang Feng Core technical personnel

Chengdu Olymvax Biopharmaceuticals Headlines

No Headlines